Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pretreatment with low-dose midazolam, low-dose etomidate, or transcutaneous electrical stimulation to reduce etomidate injection pain and myoclonus
IRCT20160307026950N70Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of midazolam and etomidate in pain and myoclonus (4 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Pain, Myoclonic movements and 2 more. Started Jul 2025; status: completed.
02
Drugs
midazolametomidate
03
Conditions
painmyoclonus
Beyond the preview
Go deeper on IRCT20160307026950N70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160307026950N70.